• Also on Monday, Abbott presented mixed results for its triglyceride-lowering drug TriCor in diabetics.

    FORBES: Abbott Heart Failure Drug Misses Goal

  • But a related Abbott drug, TriCor, failed to prove its benefits in a large randomized controlled clinical trial.

    FORBES: Why Merck's Niacin Failure Will Scare Drug Researchers

  • However, the positive trends in the study are likely to encourage other companies developing new, more powerful versions of Tricor.

    FORBES: Abbott's Cholesterol Drug Missed The Mark

  • Both Lopid and Tricor are thought to work by targeting a molecular signal called the peroxisome proliferators activator receptor (PPAR) alpha.

    FORBES

  • Grundy points out that patients in the placebo group seem to have received cholesterol drugs more often than those who got Tricor.

    FORBES: Abbott's Cholesterol Drug Missed The Mark

  • There was every reason to expect that Tricor, a pill sold by Abbott Laboratories, would reduce heart attack or death from heart disease.

    FORBES

  • Lots of data had hinted at Tricor's potential.

    FORBES

  • Tricor did decrease heart attacks by a statistically significant 24%, and it made it less likely that patients would have to undergo heart surgery or angioplasty, a procedure in which balloons are used to unclog arteries.

    FORBES: Abbott's Cholesterol Drug Missed The Mark

  • Abbott shares were down 3.9% in morning trading on mixed results for the heart-failure drug, levosimendan or Simdax, and another drug, Tricor, which was aimed at further reducing heart problems in diabetics on top of conventional therapy.

    FORBES: Magazine Article

  • Scott Grundy, a cardiologist at the University of Texas Southwestern who helped write the U.S. cholesterol guidelines, argued that overall the results of the study do show that Tricor was a useful addition on top of current treatment.

    FORBES: Abbott's Cholesterol Drug Missed The Mark

  • But today, at the annual Scientific Sessions of the American Heart Association and in the medical journal Lancet, researchers announced that Tricor failed to stop heart attacks and prevent deaths in a five-year study of almost 10, 000 diabetics.

    FORBES: Abbott's Cholesterol Drug Missed The Mark

  • It was, so I'm on TriCor.

    NPR: Varied Responses to Cholesterol Worries

  • Abbott (nyse: ABT - news - people ) shares were down 3.9% in morning trading on mixed results for the heart-failure drug, levosimendan or Simdax, and another drug, Tricor, which was aimed at further reducing heart problems in diabetics on top of conventional therapy.

    FORBES: Open Questions For Heart Failure Drugs

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定